Monopar Therapeutics Inc. (NASDAQ:MNPR) Major Shareholder Tactic Pharma Llc Sells 33,334 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares of the company’s stock, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR traded down $4.59 during midday trading on Friday, hitting $30.00. 42,416 shares of the company’s stock traded hands, compared to its average volume of 358,675. The firm has a fifty day moving average of $38.29 and a 200 day moving average of $24.88. Monopar Therapeutics Inc. has a 1 year low of $1.72 and a 1 year high of $54.30. The stock has a market capitalization of $183.39 million, a price-to-earnings ratio of -15.23 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($1.87). On average, equities analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics during the fourth quarter valued at $45,000. Geode Capital Management LLC raised its stake in shares of Monopar Therapeutics by 174.4% in the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after buying an additional 24,530 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Monopar Therapeutics during the 4th quarter valued at about $2,861,000. Point72 Asset Management L.P. bought a new position in shares of Monopar Therapeutics during the 4th quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $11,247,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MNPR. Piper Sandler reaffirmed an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Monopar Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.00.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.